Evaluation of VesiVax Adjuvant Formulations for HIV Vaccines

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 75N93019C00007
Agency Tracking Number: N43AI190007
Amount: $599,983.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: N/A
Timeline
Solicitation Year: 2018
Award Year: 2019
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
2630 HOMESTEAD PLACE, RANCHO DOMINGUEZ, CA, 90220-5610
DUNS: 058878682
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Sam Ho
 (310) 635-5502
 sho@molecularexpress.com
Business Contact
 Sam Ho
Phone: (310) 635-5502
Email: sho@molecularexpress.com
Research Institution
N/A
Abstract
This proposal aim to develop a VesiVaxplatform based liposomal vaccine that can co formulate the HIV antigenHIV Env gpAwith various immunotimulatory adjuvant moleculesIAMsThe IAMs that we will formulate with the antigen includeslipidated tucaresolmuramyl tripeptide phosphatidylethanolaminePam CAGmonophosphoryl lipid AdsRNAandcyclic dinucleotidesThe formulations will be evaluated in miceand selected formulations with the highest specific antibody titers will be optimized for antigen and adjuvant doses

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government